| AbbVie14 programs in shared conditions | 6 · 3 with both in phase 3Colitis, Ulcerative, Crohn Disease, Dermatitis, Atopic +3 | risankizumab, vedolizumab, upadacitinib | - AbbVie’s upadacitinib in a combination vs dupilumab (EU rights: Sanofi) (Dermatitis, Atopic, NCT06389136)
- AbbVie’s zumilokibart in a combination vs dupilumab (EU rights: Sanofi) (Dermatitis, Atopic, NCT07027527)
- AbbVie’s APG990 in a combination vs dupilumab (EU rights: Sanofi) (Dermatitis, Atopic, NCT07027527)
|
| Innovent Biologics, Inc.4 programs in shared conditions | 1 · 1 with both in phase 3Dermatitis, Atopic | IBI3027 | - Innovent Biologics, Inc.’s IBI356 in a combination vs dupilumab (EU rights: Sanofi) (Dermatitis, Atopic, NCT07330934)
- Innovent Biologics, Inc.’s IBI3027 in a combination vs dupilumab (EU rights: Sanofi) (Dermatitis, Atopic, NCT07754786)
- Innovent Biologics, Inc.’s IBI3002 in a combination vs dupilumab (EU rights: Sanofi) (Dermatitis, Atopic, NCT07399067)
|
| Pfizer15 programs in shared conditions | 12 · 4 with both in phase 3Colitis, Ulcerative, Dermatitis, Atopic, Hemophilia A +9 | ibuzatrelvir, remdesivir, etrasimod +6 | - Sanofi’s Pneumococcal 21-Valent Conjugate Vaccine vs Pneumococcal 20-Valent Conjugate Vaccine (most trials: Pfizer) (Anemia, Sickle Cell, NCT07247188)
- Pfizer’s tilrekimig vs dupilumab (EU rights: Sanofi) (Dermatitis, Atopic, NCT07783425)
|
| Novartis18 programs in shared conditions | 11 · 2 with both in phase 3Multiple Sclerosis, Purpura, Thrombocytopenic, Idiopathic, Chronic Urticaria +8 | remibrutinib, delpacibart zotadirsen, AOC 1001 +1 | - Novartis’s remibrutinib vs dupilumab (EU rights: Sanofi) (Chronic Urticaria, NCT06868212)
|
| Qilu Pharmaceutical Co., Ltd.7 programs in shared conditions | 7 · 2 with both in phase 3Dermatitis, Atopic, Purpura, Thrombocytopenic, Idiopathic, Diabetes Mellitus, Type 2 +4 | QLM3003, QL2108, QLG1091 +1 | - Qilu Pharmaceutical Co., Ltd.’s QL2108 in a combination vs dupilumab (EU rights: Sanofi) (Dermatitis, Atopic, NCT06884891)
|